Latest News and Press Releases

Completed enrollment of Phase 2a small-cell lung cancer trial, with topline data expected in first quarter 2018 Closed initial public offering that raised $107.1 million in net proceeds RESEARCH...

RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, announced today that Chief Executive Officer Mark Velleca, MD,...

Terry Murdock appointed Senior Vice President, Development OperationsShannon Morris, MD, PhD, named Vice President, Clinical Development RESEARCH TRIANGLE PARK, N.C., Aug. 03, 2017 (GLOBE NEWSWIRE)...

RESEARCH TRIANGLE PARK, N.C., July 27, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that the Company will ring the Nasdaq Stock...

RESEARCH TRIANGLE PARK, N.C., July 13, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced the appointment of Sir Andrew Witty to its...

RESEARCH TRIANGLE PARK, N.C., May 30, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Phase 1b data from the ongoing Phase 1b/2a...

RESEARCH TRIANGLE PARK, N.C., May 23, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced the closing of its initial public offering of...

RESEARCH TRIANGLE PARK, N.C., May 16, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage oncology company, today announced the pricing of its initial public offering of 7,000,000...

RESEARCH TRIANGLE PARK, N.C., May 08, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (“G1” or the “Company”), a clinical-stage oncology company, today announced the commencement of the initial...

RESEARCH TRIANGLE PARK, N.C., March 29, 2017 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that it will present preclinical data on trilaciclib,...